MARKET

BLSM

BLSM

BlossomHill Therapeutics, Inc
NASDAQ
12.38
-0.03
-0.24%
After Hours: 12.38 0 0.00% 19:30 11/04 EST
OPEN
12.45
PREV CLOSE
12.41
HIGH
13.00
LOW
11.22
VOLUME
297.40K
TURNOVER
--
52 WEEK HIGH
27.99
52 WEEK LOW
11.22
MARKET CAP
393.50M
P/E (TTM)
-8.4742
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BLSM last week (1026-1030)?
Weekly Report · 2d ago
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 6d ago
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
Seeking Alpha · 10/28 12:31
Weekly Report: what happened at BLSM last week (1019-1023)?
Weekly Report · 10/26 10:34
Analysts Offer Insights on NA Companies: Turn Therapeutics Inc (TTRX) and BlossomHill Therapeutics, Inc. (BLSM)
TipRanks · 10/23 12:03
BlossomHill Therapeutics enters CDx collaboration with Foundation Medicine
TipRanks · 10/22 11:27
BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation
Benzinga · 10/22 11:06
Weekly Report: what happened at BLSM last week (1012-1016)?
Weekly Report · 10/19 10:34
More
About BLSM
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. The Company is focused on its two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). It also has a preclinical-stage product candidate, BH-501284, that leverages a novel chemical scaffold to selectively target and modulate activated KRAS. The Company is also advancing multiple discovery-stage efforts focused on validated and emerging new oncology targets.

Webull offers BlossomHill Therapeutics, Inc stock information, including NASDAQ: BLSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLSM stock methods without spending real money on the virtual paper trading platform.